JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Clin Rheumatol
; 39(3): 847-851, 2020 Mar.
Article
en En
| MEDLINE
| ID: mdl-31897953
ABSTRACT
To present our preliminary experience with JAK inhibitors in treating patients affected by juvenile idiopathic arthritis (JIA) and associated uveitis. Case series. Four consecutive patients with long-term history of juvenile idiopathic arthritis and severe associated uveitis were included in the study. Indication for treatment with JAK inhibitors was uncontrolled arthritis and/or uveitis despite different treatments with conventional and biologic disease modifying antirheumatic drugs (DMARDs). While on treatment with JAK inhibitors, namely, baricitinib (three cases) and tofacitinib (one case), all our patients showed improvement of uveitis defined as a reduction of intraocular inflammation according to Standardized Uveitis Nomenclature criteria. However, we observed a different response to treatment between the uveitis and the articular disease, as the latter did not respond as favorably as the former. Overall, the treatment was well tolerated by all patients and no ocular discomfort, ocular side effects, or allergic reactions were registered. JAK inhibitors may provide a new valuable treatment option in the therapeutic armamentarium for patients affected with JIA-associated uveitis, particularly in those refractory cases that are not adequately responding to conventional or biologic DMARDs.Key Points⢠A subset of patients with JIA uveitis either remain unresponsive or experience loss of efficacy⢠JAK inhibitors may provide a new valuable treatment option in JIA patients with uveitis⢠The safety profile was good with no occurrence of systemic side effects.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Artritis Juvenil
/
Uveítis
/
Inhibidores de las Cinasas Janus
Tipo de estudio:
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin Rheumatol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia